Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SLC6A6 | P31641 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4455275 | 0.97 | APP (0.44) | APPPTGS1PDE4ALMNASLC6A6 | |
| Ammonia Solution, Strong SCHEMBL19811951 | 0.97 | APP (0.44) | APPPTGS1PDE4ALMNASLC6A6 | |
| SCHEMBL778506 | 0.92 | APP (0.44) | APPPTGS1PDE4ALMNASLC6A6 | |
| Dimethylamine SCHEMBL19811940 | 0.91 | APP (0.39) | APPPTGS1PDE4ALMNASLC6A6 | |
| SCHEMBL28620861 | 0.90 | APP (0.42) | APPPTGS1PDE4ALMNASLC6A6 | |
| SCHEMBL19810941 | 0.90 | APP (0.42) | APPPTGS1PDE4ALMNASLC6A6 | |
| SCHEMBL4759462 | 0.90 | APP (0.42) | APPPTGS1PDE4ALMNASLC6A6 | |
| SCHEMBL19811047 | 0.90 | APP (0.42) | APPPTGS1PDE4ALMNASLC6A6 | |
| Ammonia Solution, Strong SCHEMBL19811888 | 0.90 | APP (0.42) | APPPTGS1PDE4ALMNASLC6A6 | |
| SCHEMBL19811088 | 0.90 | APP (0.42) | APPPTGS1PDE4ALMNASLC6A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 208 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023130423-A1 | ELECTROCHEMICAL DEVICE AND ELECTRONIC DEVICE COMPRISING SAME | 宁德新能源科技有限公司 | 2023-07-13 | — | — | WO | claimed |
| US-10202360-B2 | Therapeutic compounds | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-02-12 | — | — | US | claimed |
| WO-2017184462-A1 | THERAPEUTIC COMPOUNDS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-10-26 | — | — | WO | claimed |
| US-20170298040-A1 | THERAPEUTIC COMPOUNDS | CELGENE QUANTICEL RESEARCH, INC. | 2017-10-19 | — | — | US | claimed |
| EP-2222674-B1 | AMINO TRIAZOLES AS PI3K INHIBITORS | CELLZOME LTD (GB) | 2015-11-11 | — | — | EP | claimed |
| US-8865699-B2 | Amino triazoles as PI3K inhibitors | CELLZOME LTD. (GB) | 2014-10-21 | — | — | US | claimed |
| US-8088566-B2 | Photoresists; using compound containing an orgaooxygen or organosulfur compound | FUJIFILM CORPORATION (JP) | 2012-01-03 | — | — | US | claimed |
| CN-101952285-A | Amino triazoles as PI3K inhibitors | CELLZOME LTD | 2011-01-19 | — | — | CN | claimed |
| EP-2222674-A1 | AMINO TRIAZOLES AS PI3K INHIBITORS | Cellzome Limited (GB) | 2010-09-01 | — | — | EP | claimed |
| WO-2009068482-A1 | AMINO TRIAZOLES AS PI3K INHIBITORS | CELLZOME LIMITED (GB) | 2009-06-04 | — | — | WO | claimed |
| US-20090087740-A1 | NON-AQUEOUS ELECTROLYTE SECONDARY BATTERY | PANASONIC CORPORATION (JP) | 2009-04-02 | — | — | US | claimed |
| EP-1910331-A1 | PYRAZOLE DERIVATIVES AS CBl MODULATORS | AstraZeneca AB (SE) | 2008-04-16 | — | — | EP | claimed |
| WO-2007010217-A1 | PYRAZOLE DERIVATIVES AS CBl MODULATORS | ASTRAZENECA AB (SE) | 2007-01-25 | — | — | WO | claimed |
| US-20260133489-A1 | PHOTOSENSITIVE RESIN COMPOSITION, PHOTOSENSITIVE RESIN LAYER AND SEMICONDUCTOR DEVICE USING THE SAME | SAMSUNG SDI CO LTD (KR) | 2026-05-14 | — | — | US | disclosed |
| US-20260062515-A1 | PHOTOSENSITIVE RESIN COMPOSITION, PHOTOSENSITIVE RESIN LAYER, AND SEMICONDUCTOR DEVICE USING THE SAME | SAMSUNG SDI CO LTD (KR) | 2026-03-05 | — | — | US | disclosed |
| US-20260063996-A1 | PHOTOSENSITIVE RESIN COMPOSITION, PHOTOSENSITIVE RESIN LAYER AND SEMICONDUCTOR DEVICE USING THE SAME | SAMSUNG SDI CO LTD (KR) | 2026-03-05 | — | — | US | disclosed |
| EP-0486937-B1 | Hydrazone derivatives, processes for production thereof, and uses thereof | NIHON NOHYAKU CO LTD (JP) | 1995-03-22 | — | — | EP | disclosed |
| US-5358965-A | Agricultural and horticultural insecticides, activity against moths and beetles | NIHON NOHYAKU CO., LTD. (JP) | 1994-10-25 | — | — | US | disclosed |
| US-5304573-A | Insecticides | NIHON NOHYAKU CO., LTD. (JP) | 1994-04-19 | — | — | US | disclosed |
| EP-0486937-A1 | Hydrazone derivatives, processes for production thereof, and uses thereof | NIHON NOHYAKU CO., LTD. (JP) | 1992-05-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202360-B2 | Therapeutic compounds | EP300, BRDT, BRPF3 | APP 3074/4885PTGS1 1627/4885PDE4A 2724/4885 |
| US-20260133489-A1 | PHOTOSENSITIVE RESIN COMPOSITION, PHOTOSENSITIVE RESIN LAYER AND SEMICONDUCTOR DEVICE USING THE SAME | ASH2L, RER1, ARCN1 | APP 2988/4885PTGS1 373/4885PDE4A 4865/4885 |
| US-20170298040-A1 | THERAPEUTIC COMPOUNDS | EP300, BRDT, BRPF3 | APP 3074/4885PTGS1 1627/4885PDE4A 2724/4885 |
| US-20260062515-A1 | PHOTOSENSITIVE RESIN COMPOSITION, PHOTOSENSITIVE RESIN LAYER, AND SEMICONDUCTOR DEVICE USING THE SAME | RPS4Y1, ASH2L, KDM4D | APP 1988/4885PTGS1 1093/4885PDE4A 4497/4885 |
| US-20260063996-A1 | PHOTOSENSITIVE RESIN COMPOSITION, PHOTOSENSITIVE RESIN LAYER AND SEMICONDUCTOR DEVICE USING THE SAME | ASH2L, FCER2, TAS1R2 | APP 1359/4885PTGS1 520/4885PDE4A 3013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.